Massive weight loss opportunity for Novo Nordisk

14 May 2020

A weight management trial testing a 2.4 mg subcutaneous (SC) formulation of Novo Nordisk’s semaglutide has met its primary endpoint, raising the prospect of new market opportunities for the Danish firm.

A lower dose SC version of semaglutide, marketed as Ozempic, is currently approved in diabetes and for reducing the risk of major adverse cardiovascular (CV) events in people with type 2 diabetes and established CV disease.

Novo Nordisk has also developed a potentially game-changing oral formulation of the GLP-1 agonist - the first complex biologic to be administered in this way.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK